“童颜针”代理权之争：*ST苏吴提起仲裁索赔16亿元，爱美客称暂未收到仲裁文件

Core Viewpoint - The dispute over the exclusive agency rights of AestheFill (艾塑菲) between *ST Suwu and REGEN has escalated into legal proceedings, with *ST Suwu's subsidiary, Datou Medical, filing for arbitration to confirm the validity of the exclusive agency agreement and seeking significant compensation for alleged losses [1][3][5]. Group 1: Legal Proceedings and Dispute - Datou Medical has initiated arbitration at the Shenzhen International Arbitration Court, which was formally accepted on August 7, 2023, requesting confirmation of the exclusive agency agreement and continuation of supply obligations, along with a compensation claim of up to 1.6 billion yuan for various losses [3][4]. - The partnership between Datou Medical and REGEN began in August 2022, granting Datou Medical exclusive distribution rights for AestheFill in mainland China until August 28, 2032 [3][4]. - REGEN terminated the agreement citing violations by Datou Medical, including the unauthorized transfer of agency rights and reputational damage due to *ST Suwu's legal issues [4][5]. Group 2: Financial Implications - AestheFill is a critical revenue driver for *ST Suwu, with projected sales of 3.26 billion yuan in 2024, accounting for 20.42% of the company's total revenue, and a gross profit of 2.69 billion yuan, representing 34.8% of total gross profit [6]. - In Q1 2025, AestheFill's sales revenue increased to 1.13 billion yuan, making up 35.55% of total revenue, with gross profit reaching 0.92 billion yuan, which is 45.77% of total gross profit, highlighting its importance to the company's profitability [6][7]. Group 3: Market Context and Strategic Importance - The dispute over AestheFill's agency rights reflects the competitive nature of the medical aesthetics industry, where control over distribution and pricing can significantly impact revenue and profit margins [8]. - The ongoing legal battle underscores the reliance of companies in the medical aesthetics sector on blockbuster products to drive financial performance, indicating a broader trend in the industry [8].